Original article by Sally Rose
The Australian Financial Review – Page: 22 : 25-May-15

US-based AirXpanders hopes to raise $A31.9m in an Australian IPO by issuing CHESS Depository Interests at $A0.50 apiece. Proceeds of the IPO will be used to finance the commercialisation of its Aeroform medical technology for women who elect to undergo breast reconstruction surgery following a mastectomy. The technology has been approved for use in Australia and Europe.

CORPORATES
AIRXPANDERS INCORPORATED – ASX AXP, CANACCORD GENUITY (AUSTRALIA) LIMITED, GBS VENTURE PARTNERS LIMITED